The Detection Performance of 18F–Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate Cancer

Ya-Ting Huang(Saint Mary's Hospital Luodong), Yen‐Chuan Ou(Tungs' Taichung MetroHarbor Hospital), Kuo‐How Huang(National Taiwan University), Hsiu-Ying Lin(Saint Mary's Hospital Luodong), Ya-Yao Huang(China Medical University), Thomas I.S. Hwang(City of Hope), Neng-Chuan Tseng(China Medical University), Yen-Kung Chen(Fu Jen Catholic University)
Clinical Nuclear Medicine
April 22, 2022
10.1097/rlu.0000000000004228
Cited by 17

Related Papers

The MicroRNA Spectrum in 12 Body Fluids
|Clinical Chemistry|2010|2.8k
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
|The Lancet|2017|177
Aristolochic acid‐induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes
|International Journal of Cancer|2013|133
Kidney impairment in primary aldosteronism
|Clinica Chimica Acta|2011|133